Loading...
XETR
BNN
Market cap72mUSD
Jul 09, Last price  
2.91EUR
1D
3.56%
1Q
21.25%
Jan 2017
-82.94%
IPO
-69.08%
Name

BRAIN Biotech AG

Chart & Performance

D1W1MN
XETR:BNN chart
P/E
P/S
1.28
EPS
Div Yield, %
Shrs. gr., 5y
3.21%
Rev. gr., 5y
5.36%
Revenues
50m
-9.17%
7,476,28510,134,51112,987,60821,132,36322,789,95024,105,00027,051,00038,560,00038,225,00038,389,00049,509,00055,335,00054,631,00049,623,000
Net income
-12m
L+5.53%
-5,537,256-4,095,361-5,044,485-5,714,554-14,689,820-9,607,000-8,276,000-10,495,000-9,684,000-4,972,000-6,590,000-8,279,000-11,127,000-11,742,000
CFO
-9m
L+157.69%
-5,886,002-4,849,068-3,903,265-4,113,241-8,683,489-5,757,000-5,418,000-3,380,000-4,767,000-3,906,000-1,485,000-4,218,000-3,583,000-9,233,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.
IPO date
Feb 09, 2016
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT